Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01572636 · ClinicalTrials.gov registry record
Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome
A clinical trial, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- 20
- Enrollment target
NCT01572636: Clinical Trial study, sponsored by Masonic Cancer Center, University of Minnesota.
NCT01572636 is a clinical trial that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01572636 was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This is a standard of care treatment guideline for patients with the diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) who are being considered as candidates for first hematopoietic stem cell transplantation (HSCT) according to a University of Minnesota myeloablative HSCT protocol.
Primary Outcome
Patients alive at 1 year post transplantation.
Interventions
- DRUG Laronidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-03-28 |
| Est. Completion | 2018-05-01 |
Why NCT01572636 stopped before completion
NCT01572636 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Laronidase is the first listed.
NCT01572636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01572636 about?
NCT01572636 is a clinical study titled "Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome". This is a standard of care treatment guideline for patients with the diagnosis of mucopolysaccharidosis type IH (MPS I, Hurler syndrome) who are being considered as candidates for first hematopoietic stem cell transplantation (HSCT) according to a University of Minnesota myeloablative HSCT protocol.
What is the current status of trial NCT01572636?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2012-03-28. Estimated completion is 2018-05-01.
What interventions are being tested in trial NCT01572636?
The interventions under investigation include: Laronidase (DRUG).
Who is sponsoring clinical trial NCT01572636?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI